Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615828 | 0.80 | ADRB2 (0.46) | LOXL2ADRB2PDPK1SLC6A4SLC6A3 | |
| SCHEMBL10130831 | 0.80 | ADRB2 (0.43) | LOXL2ADRB2PDPK1LMNAXBP1 | |
| SCHEMBL722198 | 0.80 | PDPK1 (0.77) | LOXL2ADRB2PDPK1SLC6A4SLC6A3 | |
| SCHEMBL8240124 | 0.79 | LOXL2 (0.67) | LOXL2ADRB2PDPK1SLC6A4SLC6A3 | |
| SCHEMBL19112150 | 0.79 | LOXL2 (0.57) | LOXL2ADRB2PDPK1LMNAXBP1 | |
| SCHEMBL21791658 | 0.79 | LOXL2 (0.71) | LOXL2ADRB2PDPK1SLC6A4SLC6A3 | |
| SCHEMBL14210017 | 0.78 | LOXL2 (0.56) | LOXL2ADRB2PDPK1LMNAXBP1 | |
| SCHEMBL11994379 | 0.78 | PDPK1 (0.57) | LOXL2ADRB2PDPK1SLC6A4SLC6A3 | |
| SCHEMBL12001099 | 0.78 | ACACB (0.66) | LOXL2ADRB2ACACB | |
| Hydrochloric Acid SCHEMBL17261482 | 0.76 | LOXL2 (0.62) | LOXL2ADRB2PDPK1SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8471024-B2 | Tetrahydrofuropyridones | MERCK SHARP & DOHME, CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN (US) | 2012-02-09 | — | — | US | disclosed |
| US-20100331358-A1 | TETRAHYDROFUROPYRIDONES | MERCK SHARP & DOHME LLC | 2010-12-30 | — | — | US | disclosed |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2009-12-31 | — | — | US | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | OR YAT SUN | 2007-10-18 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135485-A1 | 6-11 BICYCLIC KETOLIDE DERIVATIVES | AKR1C2, AKR1C3, AKR1C1 | LOXL2 3872/4885ADRB2 3433/4885PDPK1 2265/4885 |
| US-20120035352-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | LOXL2 3872/4885ADRB2 3433/4885PDPK1 2265/4885 |
| US-20070244160-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | LOXL2 3872/4885ADRB2 3433/4885PDPK1 2265/4885 |
| US-20100331358-A1 | TETRAHYDROFUROPYRIDONES | HIF1AN, EGLN3, HIF1A | LOXL2 3773/4885ADRB2 2765/4885PDPK1 1449/4885 |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | LOXL2 4753/4885ADRB2 4316/4885PDPK1 4458/4885 |
| US-20090324577-A1 | 6-11 Bicyclic Ketolide Derivatives | AKR1C2, AKR1C3, AKR1C1 | LOXL2 3872/4885ADRB2 3433/4885PDPK1 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.